Breaking News, Collaborations & Alliances

Biogen Exercises Option for Exclusive License to BIIB115

BIIB115 is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen exercised its option to obtain from Ionis a worldwide, exclusive license to develop and commercialize BIIB115/ION306. The companies have a broad strategic collaboration to develop novel therapies to treat neurological disorders. BIIB115 is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy (SMA) that may have the potential to help address additional unmet needs. Biogen plans to advance BIIB115 to clinical trials to investigate safety, tolerabilit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters